bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to
combat COVID-19
Qu Deng1,*, Reyaz ur Rasool1,*, Ronnie M. Russell2, Ramakrishnan Natesan1, Irfan A.
Asangani1,3
1. Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania. 2. Department of
Microbiology, University of Pennsylvania. 3. Department of Cancer Biology, Abramson Family Cancer Research
Institute, Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard,
BRBII/III, Philadelphia, PA 19104, USA.

Electronic address: asangani@upenn.edu.
* Equal contributions with authors named in alphabetical order
Abstract
The COVID-19 pandemic is expected to have an adverse effect on the progression of multiple
cancers, including prostate cancer, due to the ensuing cytokine storm and associated oncogenic
signaling. Epidemiological data showing increased severity and mortality of COVID-19 in men
suggests a potential role for androgen in SARS-CoV-2 infection. Here, we present evidence for
the transcriptional regulation of SARS-CoV-2 host cell receptor ACE2 and co-receptor TMPRSS2
by androgen in mouse tissues and human prostate and lung cell lines. Additionally, we demonstrate
the endogenous interaction between TMPRSS2 and ACE2 in human cells and validate ACE2 as a
TMPRSS2 substrate. In an overexpression model, and the prostate and lung cells, Camostat â€“ a
TMPRSS2 inhibitor, blocked the cleavage of pseudotype SARS-CoV-2 surface Spike without
disrupting TMPRSS2-ACE2 interaction. Thus providing evidence for the first time a direct role of
TMPRSS2 in priming the SARS-CoV-2 Spike protein, required for viral fusion to the host cell.
Importantly, androgen-deprivation, anti-androgens such as enzalutamide/AR-PROTAC, or
Camostat treatment attenuated the SARS-CoV-2 S-mediated entry in lung and prostate cells.
Together, our preclinical data provide a strong rationale for clinical evaluations of the TMPRSS2
inhibitors, androgen-deprivation therapy and androgen receptor antagonists alone or in
combination with anti-viral drugs as early as clinically possible to prevent inflammation driven
COVID-19 progression.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Keywords: COVID-19, SARS-CoV-2 Spike, S priming, TMPRSS2, ACE2, Androgen Receptor,
Transcription regulation, Androgen deprivation therapy, Camostat.
Introduction
The ongoing COVID-19 (Coronavirus disease 2019) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is global health crisis (Morens and
Fauci, 2020; Wang et al., 2020). As of September 2020, more than 35 million cases of COVID-19
and one million deaths have been recorded (https://coronavirus.jhu.edu). Epidemiological data
have shown that males are disproportionally affected, being slightly more likely to be infected than
females and accounting for most severely ill cases and higher fatality. This is compounded by
older age and comorbidities such as diabetes, cardiovascular diseases, obesity, hypertension and
cancer (Williamson et al., 2020). This sex disparity with respect to increased morbidity and
mortality in men suggests a potential role for the male hormone androgen in SARS-CoV-2
infection and host response (Stopsack et al., 2020; Wadman, 2020). The host immune response to
SARS-CoV-2 potentiates a hyper-inflammatory cytokine storm involving the upregulation of
tumor necrosis factor-Î± (TNF- Î±), interleukin 1Î² (IL-1 Î²), interleukin-6 (IL-6), monocyte
chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-Î± (MIP1Î±), which is
associated with COVID-19 severity and mortality(Mehta et al., 2020; Moore and June, 2020;
Vabret et al., 2020; Zhang et al., 2020). Tumor cell-intrinsic and microenvironment associated
immune cell response to inflammation promote the development and progression of several types
of solid cancer, including prostate cancer (de Bono et al., 2020). Therefore, it is reasonable to
hypothesize that the inflammatory signaling accompanying severe COVID-19 disease could cause
cancer progression. Therefore, early intervention of COVID-19 management should be considered
in cancer patients who are more susceptible to SARS-CoV-2 infection due to their
immunosuppressive state.
SARS-CoV-2 entry into the host cell is mediated by trimers of the transmembrane spike (S)
glycoprotein. The S trimer binds to the cellular receptor angiotensin converting enzyme 2 (ACE2)
on the surface of target cells and mediates subsequent viral uptake and fusion dependent on
processing by host proteases (Hoffmann et al., 2020c).

Several host proteases, including

TMPRSS2, cathepsin B and L, and furin have been suggested to promote the entry of SARS-CoV2; how they process the Spike protein remains to be determined (Coutard et al., 2020; Shang et al.,

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

2020; Walls et al., 2020). In relevant target cells, the cleavage of S by TMPRSS2 activates the
protein for membrane fusion via extensive, irreversible conformational changes (Millet and
Whittaker, 2015; Walls et al., 2020; Walls et al., 2017). As a result, SARS-CoV-2 entry into
susceptible cells is a complex process that requires the concerted action of ACE2 receptor-binding
and TMPRSS2 proteolytic processing of the S protein to promote virus-cell fusion. Despite their
well-documented role in SARS-CoV-2 entry, the nature of endogenous ACE2 and TMRPSS2
interactions in host cells is lacking.
TMRPSS2 is a widely studied androgen-regulated gene associated with prostate cancer (Afar et
al., 2001). It contributes to prostate cancer pathogenesis by way of aberrantly driving oncogenic
transcription. More than half of all prostate cancers in men of European ancestry harbor a gene
fusion that juxtaposes the androgen receptor (AR) regulatory promoter/enhancer elements of
Tmprss2 in front of the ETS family transcription factors, most commonly Erg(Tomlins et al.,
2005). Although ERG is not normally regulated by androgen, this somatic gene rearrangement
results in oncogenic ERG expression under androgen receptor signaling. Further, TMRPSS2 is
known to promote metastatic spread of prostate cancer through HGF activation (Lucas et al.,
2014). ACE2 is a zinc-dependent metalloprotease and is expressed at high levels in the heart, testis,
and kidney and at lower levels in various tissue (Gheblawi et al., 2020). Therefore, identifying
molecular mechanisms governing the expression of TMPRSS2 and ACE2 could potentially
explain the observed disparity in SARS-CoV-2 infection-associated morbidity and mortality in
men.
In this study, we provide evidence for the AR-mediated transcriptional regulation of TMPRSS2
and ACE2 in mice and human prostate and lung cells. Specifically, androgen deprivation in mice
by castration, or anti-androgen treatment in vitro led to a reduction in TMPRSS2 and ACE2
transcript and protein levels. Furthermore, TMPRSS2 and ACE2 were found to interact in cis in
prostate and lung cells, and the inhibition of TMPRSS2 protease activity by Camostat blocked
Spike priming. Finally, androgen-deprivation, anti-androgens, or Camostat treatment attenuated
the SARS-CoV-2 pseudotype entry in lung and prostate cells, suggesting that these drug
combinations could be effective in attenuating COVID-19 disease progression in men with or
without prostate cancer.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Results
Systemic androgen deprivation affects TMPRSS2 and ACE2 expression in mice
The poor clinical outcome of COVID-19 in men suggests a potential underlying androgen-related
cause. The role of male sex hormone androgen in regulating the SARS-CoV-2 host cell receptor
ACE2 and co-receptor TMPRSS2 has been speculated (La Vignera et al., 2020; Stopsack et al.,
2020; Wadman, 2020). To evaluate the effect of androgen deprivation on TMPRSS2 and ACE2
expression in major tissues that are the primary sites for SARS-CoV-2 infection(Ziegler et al.,
2020), we performed surgical castration in adult male mice (n=3). One week post-castration, we
harvested the lung, small intestine, heart and kidney for qRT-PCR, immunoblotting, and
immunohistochemistry analysis. Seminal vesicles and prostate were used as positive controls for
systemic androgen deprivation. Tissues from the corresponding mock castrated male (n=3) and
female (n=3) served as controls (Fig.1A). First, we determined the expression of Tmprss2, Ace2
and Ar in the control tissues. Each was expressed at varying degrees, with Ar and Tmprss2 being
the highest in seminal vesicles, and ACE2 in the small intestine (Supplementary Fig. 1A).
Interestingly, a survey of adult human male tissue mRNA expression via bulk RNA-seq from the
GTEx consortium(Consortium et al., 2017) demonstrated a similar expression pattern in prostate
and small intestine for AR, TMPRSS2, and ACE2 (Supplementary Fig. 1B), suggesting a potentially
identical mechanism of regulation in man and mice. Next, as expected, the Tmprss2 expression
was highly androgen-responsive in the seminal vesicles of the castrated males compared to the
control males. (Fig. 1B). Except for the small intestine and the lung which showed a slight
downward trend, levels of Tmprss2 in the heart (with very low basal expression), and the kidney
did not display any change upon castration. However, Ace2 expression displayed a significant
downregulation in the lung and the small intestine, which was similar to the levels found in female
mice, and upregulation in the kidney tissues in the castrated male compared to controls.
Remarkably, Ace2 expression was also reduced in the hormone-sensitive seminal vesicles upon
castration (Fig. 1B), suggesting a potential role for androgen in regulating Ace2 expression in these
tissues. In concordance with the transcripts, the immunoblot analysis using total protein extracts
from tissues demonstrated a reduced TMRPSS2 and ACE2 protein levels in the lung and the small
intestine. The reduction in protein levels was much more dramatic than the transcript levels. In
contrast, the kidney tissue displayed an increase in the ACE2 protein, but not TMPRSS2,
corroborating the transcript data (Fig. 1C). Next, we performed immunohistochemistry to identify

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

the specific cell types in these tissues that display altered expression for TMPRSS2 and ACE2
proteins upon androgen deprivation. In these experiments, DU145 and VCaP prostate cancer
xenograft tissues served as a negative control for AR, TMPRSS2, and ACE2 respectively, which
showed a clear lack of staining (Supplementary Fig. S1C). As expected, the hormone-responsive
prostate luminal epithelial cells showed reduced staining for AR and TMPRSS2 in response to
castration (Fig. 1D). We also observed a small minority population of epithelial cells <5% staining
for ACE2 on the apical surface of the prostate epithelium, which was absent in the castrated group.
The identical minimal co-expression pattern of ACE2 and TMPRSS2 was also identified in human
prostate tissues, where club cells that constitute a mere 0.07% of total prostate epithelial cells and
resemble club cells in the lung were double-positive(Henry et al., 2018; Montoro et al., 2018; Song
et al., 2020). We observed no morphological changes in response to castration in lung, small
intestine and kidney tissue through H&E staining. Similar to transcripts, the AR, ACE2, and
TMPRSS2 proteins were detected in all of the tested tissue types at varying degrees (Fig. 1E). A
strong staining for TMPRSS2 was detected exclusively in the lung respiratory bronchiole
epithelium, with minimal staining of type II alveolar cells, which is consistent with the expression
pattern observed in human tissue (Stopsack et al., 2020). The staining intensity, especially in type
II alveolar cells, was reduced in the castrated group. The ACE2 staining could be observed in the
lung parenchyma, both type I and type II alveolar cells and the bronchiole epithelium apical surface
of the castrated males showed relatively lower expression. Next, the small intestine mucosa from
the control group showed positive cytoplasmic and nuclear AR staining, which were reduced in
the castrated group. TMPRSS2 displayed high staining in the crypt and lower portion of the villi
with the exception in the goblet cells, and the staining gradually diminished on the top of the villi.
ACE2 was mainly present on the apical surface of the enterocytes on the top part of the villi. These
expression patterns mirror data from human small intestinal tissue, especially ileum and jejunum
(Hamming et al., 2004; Ziegler et al., 2020). The abundance of double-positive cells was largely
reduced in the castrated male tissue due to the reduction in both ACE2 and TMPRSS2 levels.
Concerning the kidney, the AR staining was detected in the tubular cells, which was reduced upon
castration. TMPRSS2 showed positivity mainly in the proximal tubules compared to other cells,
which was reduced in the castrated group (Muus et al., 2020). Finally, a homogenous ACE2
expression was detected across kidney tissue on the apical surface of the tubular cells. In line with
the kidneyâ€™s role in the renin-angiotensin-aldosterone system, the ACE2 intensity was strongly

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

elevated in the castrated males responding to reduced blood pressure brought out by androgen
deprivation (Dubey et al., 2002). Together, these analyses clearly demonstrate that the androgen
deprivation has an effect on the expression of TMPRSS2 and ACE2, particularly in the lung, small
intestine, and kidney. Though there was a discrepancy concerning transcript and protein levels of
TMPRSS2 in the tested tissues -particularly in the kidney, post-transcriptional regulation of
TMPRSS2 by androgen regulated microRNA could not be ruled out (Nersisyan et al., 2020).

AR regulates TMPRSS2 and ACE2 expression in human prostate and lung cells
The observation that systemic androgen deprivation affects the expression of TMPRSS2 and
ACE2 in hormone-sensitive tissues such as prostate and seminal vesicles, but also in major organs
such as the lungs, small intestine, and kidney led us to investigate the direct role of AR in the
transcriptional regulation of these two critical genes beyond the prostate. Although the upstream
enhancer of Tmprss2 is a well-known target for AR (Asangani et al., 2014), we sought to identify
whether regulatory elements of Ace2 are also occupied by AR. We analyzed publicly available AR
ChIP-seq data for AR-binding sites within 50 kb of the transcription start sites (TSSs) of the
Tmprss2 and Ace2 genes in mouse prostate, comparing castration and castration followed by
testosterone injection for 3 days (Pihlajamaa et al., 2014). As expected, multiple AR peaks were
observed in the upstream of the Tmprss22 TSS in the testosterone-treated prostate, which was also
present in DHT (dihydrotestosterone) treated VCaP and LNCaP human prostate cell lines (Fig.
2a). Interestingly, the upstream region of ACE2 also showed AR binding in mouse as well as in
human prostate cells (Fig. 2A and Supplementary Fig.2). Motif analysis of the AR occupied
regions revealed the presence of androgen response elements (ARE), as well as binding sites for
other steroid receptors such as GR (Glucocorticoid Receptor) and PR (Progesterone Receptor),
and pioneering factor such as FOXA1 (Supplementary Fig.2), suggesting potential regulation of
ACE2 by other steroid hormones. Next, we wanted to investigate whether TMPRSS2 and ACE2
expression in human cells responds to androgen deprivation or anti-androgen treatment. We
cultured LNCaP cells in steroid-deprived conditions for 2, 4, and 6 days and assessed the
expression of TMPRSS2 and ACE2 compared to cells grown in steroid-proficient condition. As
one of the most androgen-responsive gene, TMPRSS2 transcript and protein levels showed
downregulation in the steroid-deprived cells compared to their steroid-proficient controls (Fig.
2B). This was accompanied by a concomitant decrease in the levels of phosphoSer81-AR (pAR),

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

an active chromatin-bound form of AR (Rasool et al., 2019). More importantly, the ACE2
transcript and the protein levels were also downregulated in the steroid-deprived cells. Treatment
with the second-generation anti-androgen enzalutamide or AR degrader ARD-69(Han et al., 2019)
led to a time-dependent reduction in the TMPRSS2 and ACE2 expression that was accompanied
by reduced pAR levels in LNCaP cells (Fig. 2C). Since lung is one of the primary site of SARSCoV-2 infection causing severe disease, we tested whether lung cells respond to androgendeprivation and anti-androgen treatment with respect to the expression of TMPRSS2 and ACE2.
First, we screened a panel of lung cancer cell lines and found H460 cells positive for AR,
TMPRSS2 and ACE2 (Fig. 2D). Similar to that observed in LNCaP cells, H460 displayed a
marked downregulation of TMPRSS2 and ACE2 accompanied by reduced pAR levels upon
androgen-deprivation, or AR targeted therapy (Fig. 2E). Interestingly, androgen induced AR
dependent upregulation of TMPRSS2 has been demonstrated in other lung cancer cell lines
(Mikkonen et al., 2010). These data clearly demonstrate a potential role of AR in regulating SARSCoV-2 receptor and co-receptor in prostate and lung cells.

TMPRSS2 interacts with ACE2 in prostate and lung cells
Having identified the androgen dependency of TMPRSS2 and ACE2 expressions in vivo in mice
and in vitro in human cell lines, we turned our attention to their function concerning SARS-CoV2 Spike (SARS-2-S) priming. Though TMPRSS2 is implicated in priming of SARS-2-S protein
(Hoffmann et al., 2020c), it is unclear whether this occurs in association with ACE2. Further,
TMPRSS2-mediated enhancement of SARS virus entry has been shown to accompany ACE2
cleavage (Shulla et al., 2011). Therefore, we studied whether TMPRSS2 and ACE2 physically
associate in an endogenous setting and examined the effect of TMPRSS2 protease inhibition on
their interaction and cleavage of ACE2. TMPRSS2 is composed of a cytoplasmic region (aa 1-84),
a transmembrane region (aa 85-105), and an extracellular region (aa 106-492). The latter is
composed of three domains: the LDLRA (LDL receptor class A) domain (residues 112-149) â€“ that
forms a binding site for calcium, the SRCR (scavenger receptor cysteine-rich) domain (aa 149242) - involved in the binding to other cell surface or extracellular proteins, and the Peptidase S1
domain (aa 256-489), which contains the protease active site: residues H296, D345, and S441 (Fig.
3a). An auto-cleavage site at aa 255-256 has been shown to allow shedding of the extracellular
region of TMPRSS2 (Afar et al., 2001). The ACE2 protein is 805 aa long and is composed of a

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

short cytoplasmic region, a transmembrane region, and an extracellular N-terminal region that
contain zinc metallopeptidase domain (Fig. 3A). TMPRSS2 mediated cleavage of ACE2 at its Nterminus (residues 697 to 716) was shown to be required for ACE2 to interact with SARS-S protein
in 293T overexpression system (Heurich et al., 2014; Shulla et al., 2011). Our experiments show
that overexpression of TMPRSS2 in HEK293-T cells that stably express ACE2 led to ACE2
cleavage, resulting in reduced levels of the âˆ¼120 kDa full-length form and increased levels of a
âˆ¼20 kDa C-terminal fragment (Fig. 3B), as previously documented (Shulla et al., 2011).
Importantly, the treatment of cells with Camostat â€“ a TMPRSS2 serine protease inhibitor (Kawase
et al., 2012) (Fig. 3C), entirely blocked ACE2 cleavage, suggesting ACE2 as a bona fide substrate
of TMPRSS2(Shulla et al., 2011). Intriguingly, Camostat treatment did not result in any change in
ACE2 full-length levels in LNCaP cells (Supplementary Fig. 3). This observation led us to address
the existence of TMPRSS2-ACE2 complex in the endogenous setting. Towards that, we
determined the physical interaction between TMPRSS2 and ACE2 protein using N- and Cterminal specific antibodies (Fig. 3A). Reciprocal immunoprecipitation experiments showed an
endogenous association between TMPRSS2 and ACE2 in LNCaP prostate cells (Fig. 3D).
Likewise, Calu-3 lung cells demonstrated a physical interaction between TMPRSS2 and ACE2
(Fig. 3E). Along with the full-length 50 kDa TMPRSS2, a smaller approximately 38 kDa variant
was found to interact with ACE2 prominently in both the cell lines. Notably, the treatment of cells
with Camostat did not reduce the amount of ACE2 being pulled down by TMPRSS2 and viceversa, suggesting the endogenous TMPRSS2-ACE2 complex to be stable and is not dependent on
proteolytic cleavage. These data demonstrate for the first time an endogenous association between
TMPRSS2 and ACE2 in prostate and lung cells.

TMPRSS2 inhibition blocks S priming without affecting its interaction with ACE2
Next, we addressed the role of TMPRSS2 on priming of SARS-CoV-2 Spike (SARS-2-S) â€“ a
heavily glycosylated transmembrane protein (Cai et al., 2020; Ke et al., 2020) (Fig. 4A). The
unprocessed Spike S0 protein encoded by the SARS-CoV-2 genome is 1,273 amino acid long. It
is incorporated into the viral membrane and facilitates viral entry into target cells. Similar to SARS
CoV and MERS CoV Spike proteins, SARS-CoV-2 Spike consists of a proprotein convertase
(PPC) motif at the S1/S2 boundary cleaved by furin protease and TMPRSS2 into two fragments â€“
the receptor-binding fragment S1 and the membrane fusion fragment S2(Hoffmann et al., 2020b;

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Hoffmann et al., 2020c; Iwata-Yoshikawa et al., 2019; Shang et al., 2020; Shulla et al., 2011; Zhou
et al., 2015). Though the role of TMPRSS2 in SARS-2-S priming has been suggested (Hoffmann
et al., 2020c), direct evidence demonstrating the cleaving of SARS-2-S by endogenous TMPRSS2
is lacking. Therefore, we performed experiments to specifically address the role of ectopically
expressed or endogenous TMPRSS2 in SARS-2-S activation. Transfection of codon optimized
plasmid encoding SARS-2-S protein and 2xStrep.tag (Gordon et al., 2020) in HEK293-T showed
a distinct âˆ¼180 kDa, and a âˆ¼280 kDa band which is likely the differentially glycosylated S0
protein. The two other bands at âˆ¼120 kDa and a âˆ¼60 kDa could be the non-glycosylated fragments
(Fig. 4B). The S1 fragment could not detected in the immunoblots as the streptavidin-tag is located
at the C-terminal end of the constructs. The co-transfection with TMPRSS2 plasmid led to
cleavage of S0 into distinct bands corresponding to S2, and S2â€™ (Fig. 4B). Interestingly, the âˆ¼280
kDa band and âˆ¼120 kDa was fully processed by TMPRSS2, suggesting the S1/S2 site on
glycosylated and non-glycosylated S0 protein could be equally targeted by TMPRSS2 for
cleavage. The smaller fragments observed is most likely the TMPRSS2 cleaved S2 and S2â€™ from
the non-glycosylated S0. To further demonstrate the action of TMPRSS2 on S activation, we
performed spinoculation with pseudotype virus that contain replication deficient human
immunodeficiency virus (HIV) particles bearing SARS-2-S proteins in TMPRSS2 negative
HEK293-T ACE2 cells. First, the Mass spectrometry-based sequencing of pseudotype
incorporated SARS-2-S identified the prominent âˆ¼180 kDa and âˆ¼120 kDa fragments as full-length
S0 proteins, suggesting the presence of uncleaved Spike on the pseudotype (Fig. 4C and
Supplementary Fig. 4). In agreement with a recent study that demonstrated the existence of S
mostly in the closed uncleaved pre-fusion confirmation on the authentic SARS-CoV-2 (Turonova
et al., 2020), the purified pseudotype SARS-2-S virus spinoculation followed by immunoblotting
displayed both glycosylated âˆ¼180 kDa and non-glycosylated âˆ¼120 kDa full-length S0 protein
(Fig. 4D). Next, the cells transfected with TMPPSS2 plasmid showed clear processing of
pseudotype full-length S0 into S2, and S2â€™. As expected, pretreatment with Camostat prevented
the TMPRSS2 mediated cleavage of pseudotype S0. Since we had observed proteolytic cleavage
of ACE2 by TMPRSS2 in the overexpression model (Fig. 3B), we sought to observe whether the
TMPRSS2 mediated cleavage of SARS-2-S is taking place in the presence of ACE2. Toward this,
we performed immunoprecipitation of TMPRSS2 on pseudotype SARS-2-S spinoculation in the
presence or absence of Camostat. Increased pulldown of uncleaved full-length S0 was observed in

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

the Camostat treated cells compared to control, due to the inhibition of TMPRSS2 protease activity
and resulting lack of S priming (Fig. 4E). Interestingly, the amount of ACE2 pulled down by
TMPRSS2 was not affected by Camostat, suggesting the SARS-2-S cleavage by TMPRSS2 is
mediated in the presence of ACE2 in the complex. Noticeably, the cleaved S0 fragments were
completely absent in the TMPRSS2 pulldown, suggesting that once processed, the S2 and S2â€™
fragments are released from the TMPRSS2-ACE2 complex. Similar observations of pseudotype
SARS-2-S cleavage by endogenous TMPRSS2 in the presence of endogenous ACE2 were made
with LNCaP and Calu-3 cells (Fig. 4F and 4G). These data clearly demonstrate the crucial role
played by TMPRSS2 in SARS-CoV-2 viral fusion to the host cell by Spike protein priming (Fig.
4H).

Camostat alone or in combination with AR directed therapies reduces SARS-2-S
pseudovirus entry into prostate and lung cells
After identifying the role of androgen in regulating TMRPSS2 and ACE2 expression, and
TMPRSS2 mediated SARS-2-S priming, we asked whether therapeutic intervention targeting AR
and TMPRSS2 protease function could affect SARS-CoV-2 infection in prostate and lung cells.
Replication-defective virus particles bearing SARS-2-S proteins faithfully reflect critical aspects
of SARS-CoV-2 host cell entry (Hoffmann et al., 2020c). Therefore, we employed HIV
pseudotypes bearing SARS-2-S and nano-luciferase reporter to test the efficacy of Camostat and
AR directed therapies in blocking cell entry (Fig. 5A). We first asked whether androgen
deprivation could affect pseudotype virus entry by reducing TMRPSS2 and ACE2 (Fig.2). LNCaP
cells grown in the androgen proficient condition were readily susceptible to the entry driven by
SARS-2-S (Fig. 5B). However, cells grown under steroid-deprived condition (CSS- charcoal
stripped serum) demonstrated a significant reduction in the entry of pseudotype virus.
Interestingly, Camostat treatment efficiently blocked the SARS-2-S mediated entry only in the
androgen proficient condition, suggesting the presence of TMPRSS2 as a requirement for its
potency. Next, we treated LNCaP cells grown in normal growth condition with anti-androgen
enzalutamide, AR degrader ARD-69, or Camostat and observed a significant reduction in SARS2-S driven entry compared to the DMSO control. Notably, the combination of Camostat with
enzalutamide or ARD-69 was more efficacious in blocking the entry than single drug (Fig. 5C).
Since lungs are the primary target of SARS-CoV-2, we tested whether androgen deprivation,

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

enzalutamide, ARD-69 and Camostat could block SARS-2-S mediated entry in AR positive H460
cells. Similar to LNCaP cells, pseudovirus entry was significantly reduced in the H460 cells grown
in the steroid-deprived condition, enzalutamide, and ARD-69 alone or in combination with
Camostat compared to the control (Fig. 5D and 5E). As expected, compared to Camostat, the
enzalutamide or AR degrader treatment in AR-negative Calu-3 cells did not block the SARS-2-S
mediated entry (Fig. 5F). Importantly, unlike SARS-2-S, HIV pseudotypes bearing VSV-G did
not display any significant difference in cell entry under these condition in all three tested cell lines
(Supplementary Fig. 5). These results indicate that the treatment of AR-positive prostate and lung
cells with AR directed therapies in combination with TMPRSS2 inhibitor efficiently block SARS2-S mediated viral entry.
Discussion
Early intervention of SARS-CoV-2 infection could prevent cytokine storm mediated progression
to severe pneumonia and multi-organ failure in COVID-19 patients (Mehta et al., 2020). Although
the source of the cytokine storm that causes multi-organ dysfunction is not yet clear, uncontrolled
viral replication may contribute to COVID-19 severity and death. The present study provides
evidence that the expression of SARS-CoV-2 host cell receptor ACE2 and co-receptor TMPRSS2
is regulated in part by the male sex hormone androgen. Further, our data provide evidence that the
cell entry of SARS-CoV-2 Spike pseudovirus can be blocked by androgen deprivation, antiandrogens, or clinically proven inhibitors of TMPRSS2. Although other studies have demonstrated
the role of TMRPSS2 in SARS-CoV-2 Spike priming(Hoffmann et al., 2020c), we provide the
first direct evidence for the endogenous interaction between TMPRSS2 and ACE2 in human cells,
and endogenous TMPRSS2 mediated cleavage of SARS-CoV-2 Spike, which could be blocked by
Camostat. This finding is consistent with work demonstrating the role of TMRPSS2 in activating
Spike glycoproteins of closely related SARS-CoV and MERS-CoV (Iwata-Yoshikawa et al., 2019;
Zhou et al., 2015). Our observation through immunoprecipitation experiments that TMPRSS2ACE2 exists in complex and potentially required for Spike cleavage has implications for
developing novel therapeutics targeting the TMPRSS2-ACE2 interface to block Spike activation.
Collectively, our results indicate that androgen regulated TMPRSS2 promotes SARS-CoV-2 entry
by two separate mechanisms: ACE2 interaction/cleavage, which might promote viral uptake; and
SARS-2-S cleavage, which activates the S protein for membrane fusion (Hoffmann et al., 2020a;

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Hoffmann et al., 2020c). These results have important implications for our understanding of male
bias in COVID-19 severity and mortality, and provide a strong rationale for androgen deprivation
or anti-androgen therapy in men with SARS-CoV-2 infection.
The evidence provided by our data and previous studies (Mikkonen et al., 2010) suggests androgen
receptor mediated regulation of TMPRSS2 expression in non-prostatic tissues, including lung,
may explain the increased susceptibility of men to COVID-19 severity and mortality. Additionally,
ACE2 expression has been associated with androgen levels in men, where a lower ACE2 level was
associated with older men as a consequence of lower androgen (Chen et al., 2020).
Mechanistically,

besides

androgen,

other

steroid

hormones

(estrogen,

progesterone,

glucocorticoids) may also enhance TMRPSS2 and ACE2 expression in multiple tissues through
binding of their respective nuclear receptors to responsive cis elements (ERE, PRE, GRE), which
are similar to the ARE present in the gene promoter/enhancer. In addition to the regulation of
TMRPSS2 and ACE2 expression, androgen could also increase the SARS-CoV-2 severity in men
by modulating the immune response. Androgen is known to increase circulating neutrophils,
increase secretion of IL-10, IL-2, IL-8 and TGF-ð›½ by immune cells, and decrease the antibody
response to viral infections(Klein and Flanagan, 2016). It is worth noting that severe cases of
COVID-19 exhibit increased neutrophils and IL-8(Barnes et al., 2020; Takahashi et al., 2020).
Except for dexamethasone, which reduces mortality (days alive and free of mechanical ventilation)
in ICU patients by reducing inflammation (Tomazini et al., 2020), and Remdesivir, which reduces
disease duration by inhibiting viral replication (Goldman et al., 2020), there are currently no drugs
for COVID-19. There is an urgent need for prophylactic and therapeutic interventions for patients
with existing comorbidities such as cancer as they are at high risk for severe disease due to a weak
immune system. Due to an apparent male bias and assumed role of androgen in COVID-19,
multiple studies have advocated androgen deprivation therapy (ADT) and anti-androgens â€“ a
mainstay of prostate cancer treatment, as potential therapeutic options in COVID-19, which could
potentially provide protection against SARS-CoV-2 infection or at least reduce viral amplification
(Bhowmick et al., 2020; Mjaess et al., 2020; Montopoli et al., 2020; Patel et al., 2020; Stopsack et
al., 2020). Following these assumptions, various clinical trials testing ADT and anti-androgen have
begun: Degarelix (GnRH antagonist) NCT04397718, Dutasteride (ADT) NCT04446429,
Bicalutamide (first generation anti-androgen) NCT04374279, and Enzalutamide (second-

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

generation anti-androgen) NCT04475601. However, a direct link for androgen regulation of
TMPRSS2 and ACE2 in tissues, including the lung, was not established until now. Additionally,
Camostat mesilate â€“ the TMPRSS2 inhibitor which is approved for pancreatitis in Japan (Ohshio
et al., 1989), is currently being investigated as a treatment for COVID-19 in several active clinical
trials in USA (NCT04353284, NCT04470544, NCT04374019), Israel (NCT04355052), and
Denmark (NCT04321096). Our data showing complete block of TMRPSS2 mediated Spike
activation by Camostat in multiple cell line models provide further credentials for these clinical
trials.
Growing evidence suggests cancer patients are susceptible to severe form of COVID-19 mainly
due to their immunosuppressive state and co-existing medical conditions (Dai et al., 2020; Lee et
al., 2020; Tang and Hu, 2020). In general, patients with metastatic cancers infected with SARSCoV-2 have had poorer outcomes including death, admission to the intensive care unit, requiring
mechanical ventilation, and severe symptoms (Dai et al., 2020). As the development of vaccines
and anti-viral drugs against the pandemic causing SARS-CoV-2 are proceeding rapidly, Camostat
mesilate along with androgen regulation of TMPRSS2 and ACE2, as a means to inhibit SARSCoV-2 cell entry (Fig. 5G), and thus, the infection represents a potential strategy in treating
COVID-19 in these high-risk population.

Figure Legends:
Figure 1: Effect of androgen deprivation by castration on the expression of TMPRSS2 and
ACE2 in adult male mice. (A) Schematic depicting the castration experiment in 8-9 week-old
wild-type C57BL/6J mice. (B) Varying effect of systemic androgen deprivation on the
transcription of TMPRSS2 and ACE2 in major organs. qRT-PCR analysis for TMPRSS2 and
ACE2 transcripts in the indicated organs from mock, castrated male and normal females. Highly
hormone-responsive seminal vesicles from the male mice served as a positive control for the effect
of androgen deprivation on the target genes. (C) Immunoblot analysis showing the levels of
TMPRSS2, ACE2, and AR proteins in the indicated organs from two separate mock vs. castrated
males. Î²-Actin served as a loading control. (D) Immunohistochemistry analysis of the indicated
target protein in the prostate from mock and castrated males. Note the reduced TMPRSS2 staining
in the castrated group, and lack/sparse ACE2 staining in both groups. (E) As in d for the indicated

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

organs. Staining for AR was observed in all the tested organs. Note the reduced TMPRSS2 staining
in the bronchial epithelium of lung, columnar epithelium of small intestine, and proximal
convoluted tubules in the kidney, in the castrated group. Also, note the reduced ACE2 staining in
alveolar epithelium of the lungs and columnar epithelium of small intestine, and increased staining
in the kidney from the castrated group. Also, see supplementary Figure 1a-c. * p < 0.05 (Studentâ€™s
t-test).
Figure 2: AR-mediated transcriptional regulation of TMPRSS2 and ACE2 in human
prostate and lung cells. (A) TMPRSS2, and ACE2 loci display enhanced AR-binding upon
testosterone stimulation. Shown are AR ChIP-seq peaks around TMPRSS2 and ACE2 locus (the
red arrow indicates the TSS) in the vehicle and testosterone-treated conditions in mouse prostate
tissue (GSE47192) and human prostate cell lines. (B) Androgen deprivation, anti-androgen or ARdegradation results in the loss of TMPRSS2 and ACE2 expression. Top, qRT-PCR analysis for
TMPRSS2 and ACE2 transcripts in human prostate cells â€“ LNCaP, grown in the indicated
conditions; Reg. media â€“ Regular media with 10% serum, CSS â€“ charcoal striped serum, Enza. â€“
Enzalutamide at 25 ï­M, ARD69 â€“ AR degrader at 250nM. Bottom, immunoblot analysis for the
indicated protein. GAPDH was used the loading control. (C) Immunoblot showing the expression
of AR, TMPRSS2, ACE2 and GAPDH protein in a panel of human lung cell lines, LNCaP was
used as the positive control. (D) qRT-PCR, and immune blot analysis as in b for human lung cell
line H460. Also, see supplementary Figure 2.
Figure 3: TMPRSS2 physically interacts with ACE2 in prostate and lung cells. (A) Schematic
showing the domain structure of human TMPRSS2 and ACE2 protein. The TMRPSS2 cleavage
site on ACE2 is shown with red bar.

Epitopes recognized by the antibodies used in the

immunoprecipitation are indicated. (B) TMPRSS2 cleaves ACE2. HEK 293T ACE2 cells were
transfected with TMPRSS2 encoding plasmid, and 6h post transfection the cells were treated with
DMSO or Camostat (250 ï­M). 48h post-transfection, proteins were extracted and used for
immunoblotting with anti-ACE2, anti-TMPRSS2, and anti-GAPDH antibody. (C) Chemical
structure of Camostat. (D) TMPRSS2 and ACE2 physically interacts and is not disrupted by
Camostat â€“ a TMPRSS2 inhibitor. Reciprocal immunoprecipitation using the indicated antibodies
with LNCaP protein extracts. Cells were treated with DMSO or Camostat (250 ï­M) for 24hr
followed by protein extraction. Note, along with the full-length ~50kDa TMPRSS2 protein, the

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

presence of a novel approximately 38kDa cleaved form detected in both N-terminal and C-terminal
TMPRSS2 antibody pulldown and ACE2 pulldown. IgG pulldown served as a negative control;
inputs were 5-10%. (E) As in D with Calu-3 protein extracts.
Figure 4: TMPRSS2 in complex with ACE2 cleaves SARS-CoV-2 Spike protein.
(A) Schematic representation of the expression construct of full-length SARS-CoV-2 spike (S0)
protein that has S1 and S2 segments involved in virus attachment and fusion, respectively.
Segments of S1 include RBD, receptor-binding domain; S1/S2 cleavage site; S2 has an S2â€™
cleavage site. Tree-like symbol denotes glycans, and the C terminus contains 2x Strep-tag. The
TMPRSS2 cleavage site on S1/S2 and S2â€™ site is indicated with the resulting length of the S2 and
S2â€™ protein. Cleaved S2 and S2â€™ fragment lengths are shown. (B) TMPRSS2 cleaves glycosylated
SARS-2-S protein. HEK 293T cells were transfected with SARS-2-S plasmid with or without
TMPRSS2 encoding plasmid. 48h post-transfection, proteins were extracted and used for
immunoblotting with anti-Streptavidin, anti-TMPRSS2, and anti-GAPDH antibody. The open
arrow and * indicates the glycosylated non-glycosylated uncleaved S0 protein, respectively. The
filled arrow black indicates TMPRS2 cleaved S2 and S2â€™. The filled gray arrow indicates
TMPRSS2 cleaved potential S2 and S2â€™ fragments arising from non-glycosylated S0. (C) MS
analysis of pseudotype incorporated S0 protein. SARS-2-S pseudovirus was directly subjected to
streptavidin-IP, followed by MS analysis for sequencing. Histograms show peptide coverage for
the two prominent bands detected with in IP-western (See supplementary figure 4). (D) Pseudotype
SARS-CoV-2 Spike is cleaved by TMPRSS2, which is blocked by Camostat. HEK 293T ACE2
overexpressing cells were transfected with TMRPSS2 plasmid, 48h later cells were pretreated with
500 ï­M Camostat for 4h followed by pseudovirus inoculation by spinoculation for 1h. Next, 4h
post-spinoculation recovery total lysates were prepared and used for immunoblotting with the
indicated antibody. VSV-G containing pseudotype virus served as a negative control, and HIVp24
served as a positive control for viral inoculation. (E) Camostat blocks TMRPSS2 mediated
cleavage of S0 without disrupting the interaction between TMPRSS2-ACE2-Spike S complex.
Lysate from c was used to immunoprecipitate TMPRSS2 using N-terminal antibody followed by
immunoblotting for the indicated target. Note the increased pulldown of uncleaved Spike S0 by
the TMPRSS2 and the complete absence of S2, S2â€™, and other cleaved fragments in both DMSO
and Camostat lane. (F) Camostat reverse the endogenous TMPRSS2 mediated Spike cleavage in
human prostate and lung cells. The LNCaP and Calu-3 cells were pretreated with Camostat (500

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

ï­M) for 4hr followed by pseudotype VSV-G or SARS-CoV-2 particle spinoculation for 1h and
processed as in D. (G) Camostat blocks TMRPSS2 mediated cleavage of S0 and S2 without
disrupting the interaction between TMPRSS2-ACE2-Spike S complex in LNCaP and Calu-3 cells.
Lysate from e was used to immunoprecipitate TMPRSS2 using N-terminal antibody followed by
immunoblotting for the indicated target. Note the increased pulldown of Spike S0 by the
TMPRSS2 and the lack of S2, S2â€™ and other fragments in the Camostat lane. (H) Schematic
showing the interaction between Spike S, ACE2 and TMPRSS2 leading to cleavage of Spike S
into S1, S2 and S2â€™ segments. S0/S1 continues to bind tightly through its RBD to ACE2 that is in
complex with TMPRSS2, whereas upon cleavage the S2 and S2â€™ gets dissociated from the
TMPRSS2-ACE2 complex.
Figure 5: AR targeted therapy in combination with Camostat attenuates the entry of
pseudotype SARS-CoV-2 in to the host cells. (A) Schematic depicting the SARS-CoV-2 Spike
S pseudovirus entry assay. The pseudotype consists of Spike S, and nano-luciferase reporter. (B)
Androgen deprivation attenuates pseudotype entry. LNCaP cells grown in androgen-deprived
serum containing media for three days were pretreated with DMSO, DHT (10 nM) or Camostat
(300 ï­M) for 1h followed by inoculation with SARS-CoV-2 Spike S pseudovirus. 24h postinoculation, the pseudovirus entry efficiency was measured by means of nano-luciferase signal
accompanying entry. The entry efficiency in the DHT treated cells was taken as 100%. Error bar
indicates SEM (n =5). (C) Anti-androgens or AR degraders with or without Camostat attenuate
pseudovirus entry. LNCaP cells grown in complete media was pretreated with enzalutamide (10
ï­M) or ARD-69 (500 nM) alone, or in combination with Camostat (300 ï­M) for 1h followed by
inoculation with pseudovirus. 24h post-inoculation reporter activity measured as in d. (D) & (E),
as in c and d with AR positive H460 lung cells. (F) AR negative Calu-3 cells does not respond to
anti-androgens. Calu-3 cell are pretreated with enzalutamide, ARD-69 or Camostat followed by
pseudovirus inoculation. 24h later reporter signal characterizes the pseudovirus entry efficiency.
Error bar indicates SEM (n =5). * P < 0.05 , **P< 0.005 , ***P< 0.0005 (Studentâ€™s t test). (G)
Schematic depicting the role of TMPRSS2 in SARS-CoV-2 Spike cleavage, and androgen
mediated expression of ACE2 and TMPRSS2 that could potentially be targeted by AR directed
therapies.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Author Contributions
I.A.A. conceived the work. I.A.A., Q.D, and R.U., designed the experiments. Q.D., R.U. and R.R
performed the experiments and acquired the data. R.N. performed bioinformatics analysis. Q.D,
R.U., R.N., and I.A.A., interpreted the data, and prepared the figures. I.A.A. wrote the manuscript
with help from all the authors.
Acknowledgments
We thank Drs. PÃ¶hlmann (UG, Germany), Krogan (UCLA), and Hatziioannou (RU) for SARSCoV-2 ORFs, nano-luciferase constructs and HEK 293T ACE2 cells. We also thank the Molecular
Pathology and Imaging Core (University of Pennsylvania) for histology services, and CHOP
Proteomics Core for the mass spectrometry analysis. Research in I.A.A laboratory is supported by
NIH (1-R01 CA249210-0), Department of Defense Idea Development Award (W81XWH-170404), and Sarcoma Foundation of America Research Award to I.A.A.
Corresponding author
Correspondence to: Irfan A. Asangani (asangani@upenn.edu)

Reference
Global Health 5050. COVID-19 sex-disaggregated data tracker: Sex, gender and COVID-19
(2020).
Afar, D.E., Vivanco, I., Hubert, R.S., Kuo, J., Chen, E., Saffran, D.C., Raitano, A.B., and
Jakobovits, A. (2001). Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in
its secretion by prostate and prostate cancer epithelia. Cancer Res 61, 1686-1692.
Asangani, I.A., Dommeti, V.L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J.,
Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014). Therapeutic targeting of BET
bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282.
Barnes, B.J., Adrover, J.M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J.M.,
Dassler-Plenker, J., Guerci, P., Huynh, C., Knight, J.S., et al. (2020). Targeting potential drivers
of COVID-19: Neutrophil extracellular traps. J Exp Med 217.
Bhowmick, N.A., Oft, J., Dorff, T., Pal, S., Agarwal, N., Figlin, R.A., Posadas, E.M., Freedland,
S.J., and Gong, J. (2020). COVID-19 and androgen-targeted therapy for prostate cancer patients.
Endocr Relat Cancer 27, R281-R292.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S.M., Walsh, R.M., Jr., Rawson, S., Rits-Volloch,
S., and Chen, B. (2020). Distinct conformational states of SARS-CoV-2 spike protein. Science.
Chen, J., Jiang, Q., Xia, X., Liu, K., Yu, Z., Tao, W., Gong, W., and Han, J.J. (2020). Individual
variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 19.
Consortium, G.T., Laboratory, D.A., Coordinating Center -Analysis Working, G., Statistical
Methods groups-Analysis Working, G., Enhancing, G.g., Fund, N.I.H.C., Nih/Nci, Nih/Nhgri,
Nih/Nimh, Nih/Nida, et al. (2017). Genetic effects on gene expression across human tissues.
Nature 550, 204-213.
Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., and Decroly, E. (2020). The
spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in
CoV of the same clade. Antiviral Res 176, 104742.
Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et
al. (2020). Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study
during the COVID-19 Outbreak. Cancer Discov 10, 783-791.
de Bono, J.S., Guo, C., Gurel, B., De Marzo, A.M., Sfanos, K.S., Mani, R.S., Gil, J., Drake, C.G.,
and Alimonti, A. (2020). Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer 20, 455469.
Dubey, R.K., Oparil, S., Imthurn, B., and Jackson, E.K. (2002). Sex hormones and hypertension.
Cardiovasc Res 53, 688-708.
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.C., Turner, A.J., Raizada, M.K.,
Grant, M.B., and Oudit, G.Y. (2020). Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor
and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the
Discovery of ACE2. Circ Res 126, 1456-1474.
Goldman, J.D., Lye, D.C.B., Hui, D.S., Marks, K.M., Bruno, R., Montejano, R., Spinner, C.D.,
Galli, M., Ahn, M.Y., Nahass, R.G., et al. (2020). Remdesivir for 5 or 10 Days in Patients with
Severe Covid-19. N Engl J Med.
Gordon, D.E., Jang, G.M., Bouhaddou, M., Xu, J., Obernier, K., White, K.M., O'Meara, M.J.,
Rezelj, V.V., Guo, J.Z., Swaney, D.L., et al. (2020). A SARS-CoV-2 protein interaction map
reveals targets for drug repurposing. Nature 583, 459-468.
Hamming, I., Timens, W., Bulthuis, M.L., Lely, A.T., Navis, G., and van Goor, H. (2004). Tissue
distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in
understanding SARS pathogenesis. J Pathol 203, 631-637.
Han, X., Wang, C., Qin, C., Xiang, W., Fernandez-Salas, E., Yang, C.Y., Wang, M., Zhao, L., Xu,
T., Chinnaswamy, K., et al. (2019). Discovery of ARD-69 as a Highly Potent Proteolysis Targeting

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
J Med Chem 62, 941-964.
Henry, G.H., Malewska, A., Joseph, D.B., Malladi, V.S., Lee, J., Torrealba, J., Mauck, R.J.,
Gahan, J.C., Raj, G.V., Roehrborn, C.G., et al. (2018). A Cellular Anatomy of the Normal Adult
Human Prostate and Prostatic Urethra. Cell Rep 25, 3530-3542 e3535.
Heurich, A., Hofmann-Winkler, H., Gierer, S., Liepold, T., Jahn, O., and Pohlmann, S. (2014).
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments
entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88, 12931307.
Hoffmann, M., Hofmann-Winkler, H., Smith, J.C., Kruger, N., Sorensen, L.K., Sogaard, O.S.,
Hasselstrom, J.B., Winkler, M., Hempel, T., Raich, L., et al. (2020a). Camostat mesylate inhibits
SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral
activity. bioRxiv.
Hoffmann, M., Kleine-Weber, H., and Pohlmann, S. (2020b). A Multibasic Cleavage Site in the
Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell 78, 779784 e775.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens,
T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020c). SARS-CoV-2 Cell Entry Depends on
ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280
e278.
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., and Nagata, N.
(2019). TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine
Models after Coronavirus Infection. J Virol 93.
Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., and Matsuyama, S. (2012). Simultaneous
treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents
severe acute respiratory syndrome coronavirus entry. J Virol 86, 6537-6545.
Ke, Z., Oton, J., Qu, K., Cortese, M., Zila, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt,
C.J., Cerikan, B., et al. (2020). Structures and distributions of SARS-CoV-2 spike proteins on
intact virions. Nature.
Klein, S.L., and Flanagan, K.L. (2016). Sex differences in immune responses. Nat Rev Immunol
16, 626-638.
La Vignera, S., Cannarella, R., Condorelli, R.A., Torre, F., Aversa, A., and Calogero, A.E. (2020).
Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of
Venous Thromboembolism and Hypovitaminosis D. Int J Mol Sci 21.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Lee, L.Y.W., Cazier, J.B., Starkey, T., Briggs, S.E.W., Arnold, R., Bisht, V., Booth, S., Campton,
N.A., Cheng, V.W.T., Collins, G., et al. (2020). COVID-19 prevalence and mortality in patients
with cancer and the effect of primary tumour subtype and patient demographics: a prospective
cohort study. Lancet Oncol 21, 1309-1316.
Lucas, J.M., Heinlein, C., Kim, T., Hernandez, S.A., Malik, M.S., True, L.D., Morrissey, C.,
Corey, E., Montgomery, B., Mostaghel, E., et al. (2014). The androgen-regulated protease
TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment
and promotes prostate cancer metastasis. Cancer Discov 4, 1310-1325.
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., and Hlh Across
Speciality Collaboration, U.K. (2020). COVID-19: consider cytokine storm syndromes and
immunosuppression. Lancet 395, 1033-1034.
Mikkonen, L., Pihlajamaa, P., Sahu, B., Zhang, F.P., and Janne, O.A. (2010). Androgen receptor
and androgen-dependent gene expression in lung. Mol Cell Endocrinol 317, 14-24.
Millet, J.K., and Whittaker, G.R. (2015). Host cell proteases: Critical determinants of coronavirus
tropism and pathogenesis. Virus Res 202, 120-134.
Mjaess, G., Karam, A., Aoun, F., Albisinni, S., and Roumeguere, T. (2020). COVID-19 and the
male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol.
Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C.V., Carbone, G.M.,
Cavalli, A., Pagano, F., Ragazzi, E., et al. (2020). Androgen-deprivation therapies for prostate
cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol
31, 1040-1045.
Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F., Chen, S.,
Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy includes CFTRexpressing ionocytes. Nature 560, 319-324.
Moore, J.B., and June, C.H. (2020). Cytokine release syndrome in severe COVID-19. Science 368,
473-474.
Morens, D.M., and Fauci, A.S. (2020). Emerging Pandemic Diseases: How We Got to COVID19. Cell 182, 1077-1092.
Muus, C., Luecken, M.D., Eraslan, G., Waghray, A., Heimberg, G., Sikkema, L., Kobayashi, Y.,
Vaishnav, E.D., Subramanian, A., Smilie, C., et al. (2020). Integrated analyses of single-cell
atlases reveal age, gender, and smoking status associations with cell type-specific expression of
mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target
cells. bioRxiv, 2020.2004.2019.049254.
Nersisyan, S., Shkurnikov, M., Turchinovich, A., Knyazev, E., and Tonevitsky, A. (2020).
Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory
mechanisms of ACE2 and TMPRSS2. PLoS One 15, e0235987.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Ohshio, G., Saluja, A.K., Leli, U., Sengupta, A., and Steer, M.L. (1989). Esterase inhibitors
prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis.
Gastroenterology 96, 853-859.
Patel, V.G., Zhong, X., Liaw, B., Tremblay, D., Tsao, C.K., Galsky, M.D., and Oh, W.K. (2020).
Does androgen deprivation therapy protect against severe complications from COVID-19? Ann
Oncol.
Pihlajamaa, P., Sahu, B., Lyly, L., Aittomaki, V., Hautaniemi, S., and Janne, O.A. (2014). Tissuespecific pioneer factors associate with androgen receptor cistromes and transcription programs.
EMBO J 33, 312-326.
Rasool, R.U., Natesan, R., Deng, Q., Aras, S., Lal, P., Sander Effron, S., Mitchell-Velasquez, E.,
Posimo, J.M., Carskadon, S., Baca, S.C., et al. (2019). CDK7 Inhibition Suppresses CastrationResistant Prostate Cancer through MED1 Inactivation. Cancer Discov 9, 1538-1555.
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., and Li, F. (2020). Cell entry
mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117, 11727-11734.
Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S., and Gallagher, T. (2011). A
transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus
receptor and activates virus entry. J Virol 85, 873-882.
Song, H., Seddighzadeh, B., Cooperberg, M.R., and Huang, F.W. (2020). Expression of ACE2,
the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. Eur Urol 78, 296-298.
Stopsack, K.H., Mucci, L.A., Antonarakis, E.S., Nelson, P.S., and Kantoff, P.W. (2020).
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov 10, 779782.
Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh,
J.E., Tokuyama, M., et al. (2020). Sex differences in immune responses that underlie COVID-19
disease outcomes. Nature.
Tang, L.V., and Hu, Y. (2020). Poor clinical outcomes for patients with cancer during the COVID19 pandemic. Lancet Oncol 21, 862-864.
Tomazini, B.M., Maia, I.S., Cavalcanti, A.B., Berwanger, O., Rosa, R.G., Veiga, V.C., Avezum,
A., Lopes, R.D., Bueno, F.R., Silva, M., et al. (2020). Effect of Dexamethasone on Days Alive
and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome
and COVID-19: The CoDEX Randomized Clinical Trial. JAMA.
Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., Varambally,
S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005). Recurrent fusion of TMPRSS2 and ETS
transcription factor genes in prostate cancer. Science 310, 644-648.

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Turonova, B., Sikora, M., Schurmann, C., Hagen, W.J.H., Welsch, S., Blanc, F.E.C., von Bulow,
S., Gecht, M., Bagola, K., Horner, C., et al. (2020). In situ structural analysis of SARS-CoV-2
spike reveals flexibility mediated by three hinges. Science.
Vabret, N., Britton, G.J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L.,
Moreira, A., Park, M.D., et al. (2020). Immunology of COVID-19: Current State of the Science.
Immunity 52, 910-941.
Wadman, M. (2020). Sex hormones signal why virus hits men harder. Science 368, 1038-1039.
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020).
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292
e286.
Walls, A.C., Tortorici, M.A., Snijder, J., Xiong, X., Bosch, B.J., Rey, F.A., and Veesler, D. (2017).
Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion.
Proc Natl Acad Sci U S A 114, 11157-11162.
Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020). A novel coronavirus outbreak of
global health concern. Lancet 395, 470-473.
Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J.,
Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19-related
death using OpenSAFELY. Nature 584, 430-436.
Zhang, X., Tan, Y., Ling, Y., Lu, G., Liu, F., Yi, Z., Jia, X., Wu, M., Shi, B., Xu, S., et al. (2020).
Viral and host factors related to the clinical outcome of COVID-19. Nature 583, 437-440.
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Jr., Nunneley, J.W., Barnard, D.,
Pohlmann, S., McKerrow, J.H., Renslo, A.R., et al. (2015). Protease inhibitors targeting
coronavirus and filovirus entry. Antiviral Res 116, 76-84.
Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., Cao, Y.,
Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-CoV-2 Receptor ACE2 Is an InterferonStimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across
Tissues. Cell 181, 1016-1035 e1019.

Figure 1
A

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.
Seminal Vesicle
Lung
Small Intestine
Heart
Kidney

1 .5

1 .0

1 .0
0 .5

0 .5

0 .0

1 .0

1 .0

1 .0

0 .0

*

*

1 .0

*

*

6

4

0 .5

0 .5

0 .5

0 .5
2

40X

TMPRSS2
ACE2
AR
ACTIN

t.
tra
te
Fe d
m
al
e

as

TMPRSS2

as

C

as
t.
tra
te
Fe d
m
al
e

C
k

as

C

M
oc

t.
tra
te
Fe d
m
al
e

as
C
k

as

C

AR

ACE2

Castration

MC1 MC2 CA1 CA2 MC1 MC2 CA1 CA2

H&E

0

Mock Cast.

Kidney

M
oc

as
t.
tra
te
Fe d
m
al
e
as

C

C

k

C

tra
te
d

t.
as

as

C
k

D Prostate

0 .0

C

0 .0

0 .0

M
oc

C
MC1 MC2 CA1 CA2 MC1 MC2 CA1 CA2

0 .0

8

0 .0

Heart

0 .0

M
oc

qRT-PCR, immunoblotting and IHC
for the indicated targets

Small Intestine

0 .5

0 .5

0 .5

1 .5

Major organs been harvested
8 days post surgery

Lung

1 .0

1 .0

*

0 .0

Intact

Castrated

1 .0

Ace2 fold change

Mock Cast.

1 .5

2 .0

k

2-month old B6 wild-type mice

1 .5

1 .5

M
oc

Tmprss2 fold change

B

E
H&E

40X

Kidney

Small Intestine

Lung

Mock Cast.

AR
Castrated

Mock Cast.

TMPRSS2
Castrated

Mock Cast.

ACE2
Castrated

Mock Cast.

Castrated

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
Figure(which
2 was not certified by peer review) is available
the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
under aCC-BY-NC-ND 4.0 International license.

B LNCaP (Prostate)

Cast+Veh2

AR enrichment around Tmprss2 loci (human)
VCaP_Veh
VCaP_DHT

0 .0

ACE2

1 .0

50

45

40

35

30

25

20

15

5

10

0

-5

-10

0 .5

AR enrichment around Ace2 loci (mouse)
Cast+Veh1

AR enrichment around Ace2 loci (human)
VCaP_Veh
VCaP_DHT
LNCaP_Veh
50

45

40

35

30

25

20

15

10

5

0

-5

-10

distance from TSS (kb)

E

1 .0

0 .5

TMPRSS2

TMPRSS2

ACE2

ACE2

pS81-AR

pS81-AR

AR

AR

GAPDH

GAPDH

y
Da

9
D6

AR

6-

Da

y

y

6-

Da

Da

.
za

.

En

za

En

Ve
h

icl

e

3-

y

y

Da

CS

S

6-

y

Da

Da
CS

S

2-

4-

ia

S

m

ed

ACE2

1 .5

CS

0 .0

g.

0 .0

Re

0 .5

TMPRSS2
ACE2
ACE2

1 .5

pS81-AR

GAPDH

0 .0

0 .0

Da

9

6-

Da
3-

D6

AR

D6
9

AR

En

za
.

6-

Da
3-

e
za

.

icl
Ve
h

En

ay

ay

6D

4D

S
CS

ay
S

S

2D

ed
m

CS

y

0 .5

y

0 .5

Da
y

AR

y

1 .0

ia

1 .0

g.

GAPDH

Fold mRNA expression

ACE2

0 .5

Re

TMPRSS2

1 .0

CS

aP

0

C
AR

1 .0

y

TMPRSS2

1 .5

AR

TMPRSS2

1 .5

LN

46

8

83

H

H

3
u-

ACE2

H460 (Lung)

Lung cells
al

1 .5

3-

-15

-20

-25

-30

-35

-40

-45

-50

LNCaP_DHT

D

0 .0

Ve
hi
cle
En
za
.
En 3-D
ay
za
.
6Da
AR
y
D6
9
3AR
Da
D6
y
9
6Da
y

Da
y

Da
y

6-

4-

CS
S

Da
y
2-

CS
S

ed
ia

Cast+Tes.2

CS
S

Re
g.
m

Cast+Tes.1

0 .5

0 .0

0 .0

Cast+Veh2

TMPRSS2

9

-15

-20

-25

-30

-35

-40

-45

LNCaP_DHT

mouse prostate
(GSE47192)
human prostate
cell lines

0 .5

1 .5

LNCaP_Veh

Fold mRNA expression

Fold mRNA expression

Cast+Tes.2

LNCaP (Prostate)

1 .5

1 .0

1 .0

Cast+Tes.1

distance from TSS (kb)

C

C

TMPRSS2

1 .5

Cast+Veh1

-50

human prostate
cell lines

mouse prostate
(GSE47192)

AR enrichment around Tmprss2 loci (mouse)

D6

A

Figure 3
B

A

HEK-293T ACE2

C

ACE2

Protease domain
492aa

100

C-terminal antibod y

N-terminal antibody

O

255aa

84aa 106aa

O

1aa

SRCR

LDLRA

35
25

ACE2
Extracellular

O

TM

140

TM

N

SS

PR

k

oc

M

Extracellular

Cytoplasmic

2
TM
C P
am R
o s SS
ta 2
t

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, whoMolecular
has granted bioRxiv a license to display the preprint in perpetuity. It is made
Camostat
weight (kDa) 4.0 International license.
available under aCC-BY-NC-ND
TMPRSS2

Cytoplasmic

cleaved ACE2
O

15

740 aa

antibody

70

TM

18 aa

805 aa

O

Zinc metallopeptidase domain

TMPRSS2

50

TMPRSS2 cleavage site

H2N

GAPDH

D

LNCaP

Molecular
weight (kDa)

TMPRSS2 IP

Input

SO

DM

t

os

m

Ca

P

-I

G

Ig

Molecular
weight (kDa)

ACE-2

100

35
25

TMPRSS2 IP
SO

DM

o

m
Ca

P

-I

G
Ig

G

Ig

140

ACE-2

TMPRSS2
C-terninal
antibody

40
35

Molecular
weight (kDa) Input

ACE-2

140

SO

DM

os

m
Ca

TMPRSS2
N-terminal
antibody

50
40
35
25

SO

DM

t

ta

os

am

P

-I

G

Ig

C

ACE-2

100
50

50

40

40

35

35

25

25

TMPRSS2 N-term. antibody

TMPRSS2 C-term. antibody

ACE-2 IP

t
ta
I

P

-I

gG

Molecular
Input
weight (kDa)
ACE-2

100

50

25

Molecular
weight (kDa) Input

TMPRSS2 IP

t

a
st

140

35

m

Ca

P

-I

25

Molecular
weight (kDa) Input

40

140

DM

t

ta

os

50

TMPRSS2
N-terminal
antibody

40

100

Input

SO

100

50

Calu-3

ACE-2 IP

TMPRSS2 IP
at

140

E

NH

40
40

N
H

1 aa

SO

DM

t

ta

os

m
Ca

P

-I

G

Ig

140

ACE-2

100

TMPRSS2
C-terninal
antibody

50
40
35
25

TMPRSS2 N-term. antibody

50
40
35
25

TMPRSS2 C-term. antibody

Figure 4
A

B

D

HEK-293T

E

HEK-293T ACE2

HEK-293T ACE2

S2 (fusion)

RBD

1

Strep. tag

TMPRSS2 / Furin cleavage sites

S1/S2

S0
* S2

70

S2â€™

S2â€™ - 457 aa

GAPDH

MS analysis of pseudotype S0 protein

Band # 1

a m PR S
o s S2
ta
t

C

TM

SS

2

C

TM

PR

2

a m PR S
o s S2
ta
t

SS
TM

PR

VG

TM

70

* S0

50

50

50

25

25

TMPRSS2

786
766
ALTGIAVEQDKNTQEVFAQVK

22

14

1256
1266
FDEDDSEPVLK

8
6
4
2

ACE2
100

HIV p24
GAPDH

40

Number of Spectra

34

50

TMPRSS2

25

HIV p24
TMPRSS2

50

TQLPPAYTNSFTR

12

1029
1038
814 MSECVLGQSK
796
DFGGFNFSQILPDPSKPSK

10

1256
1266
FDEDDSEPVLK

8
6
4

70

os
t
am
C

D

M
SO

ta
os

Gly.S0
140

* S0
S2

100

S2â€™

70

*

1255

1086

1038

1014

986

947

905

835

795

765

634

557

528

457

403
424

355

319

202

150

78

237

am
C

Gly.S0

260

* S0

S1

S2

ACE2
TMPRSS2
Camostat

50

50

50

IP TMPRSS2
(N-terminal ab.)

t

Gly.S0

M
SO

ta
os

SO

am
C

D
M

VS

VG

os
t
am
C

VS

VG
D
M
SO

at
100

Molecular
weight (kDa)

Gly.S0

*

H

Calu-3

IP TMPRSS2
(N-terminal ab.)

C-term

at

SARS-CoV-2
Spike
Pseudovirus

SARS-CoV-2
Spike
Pseudovirus

S0 sequence coverage = 54%

G LNCaP

Calu-3

260
140

N-term

t

F LNCaP
Molecular
weight (kDa)

C-term

S0 sequence coverage = 51%

D

N-term

113

21
77
113
150
202
237
310
346
378
403
444
466
535
567
646
786
835
905
947
995
1019
1045
1157
1255

0

21

2

TMPRSS2
100

25

HIV p24

40

GAPDH

Input

Number of Spectra

S2â€™

Band # 2

22
34
TQLPPAYTNSFTR

10

0

100

70

TMPRSS2

50
40

12

S0
* S2

50

TMPRSS2 cleavage sites
S2â€™

C

2

100

50

S2 - 587 aa

810 - SKPSKR SFI - 818

Gly. S0
140

140

100

Gly. S0

260

Gly.S0

1

140

1273

R815

680 - SPRRAR SVA - 688

Gly.S0

260

Gly.S0

S2â€™
R685

Gly.S0

260

Molecular
weight (kDa)

Input

S1 (attachment)

VS

S0

Molecular
weight (kDa)

ik
e

Molecular
weight (kDa)

Sp

SARS-CoV-2 Spike protein

S
Sp
TM ik
PR e S
SS +
2

(plasmid
bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782
; this version posted October
16, 2020. The
copyright holder for IP
this TMPRSS2
preprint
SARS-CoV-2
Spike
co-transfection)who has granted bioRxiv a license
(which was not certified by peer review) is the author/funder,
to display the preprint in perpetuity. It is made
(N-terminal
ab.)
Pseudovirus
available under aCC-BY-NC-ND 4.0 International license.

S2â€™
ACE2

50

TMPRSS2

25

HIV p24

50

TMPRSS2

S1
ACE2
TMPRSS2

S2

Figure 5
A

B

LNCaP

CSS

C

DHT

*

*

LNCaP

40
20
0

***

60
40
20

I. Virus Priming by cleavage
of spike by TMPRSS2

Cytoplasm

T

S1
S2â€™

T
T

III. Virus Replication via host machinery

AR

HSP

V. TMPRSS2 and ACE2
expression

HSP

IV.
T

T

AR

AR

HSP

T

T

AR

AR

TMPRSS2
ACE2

Flutamide
Enzalutamide
Apalutamide
Darolutamide
AR PROTAC

za
.
+

o.

C

am

+
o.
C

am

En

-6
9
D
AR

am

os
ta
t

za
.

-6
9

20

t
ta
os
C

GnRH antagonist
LHRH agonist

T
T

ACE2

Nucleus

40

D

En
+

o.
am

C

C
II. Infection: Injection of viral RNA
S0

TMPRSS2

60

.
9
-6
D
AR

am

o.

+

C

za

t
ta
os

am

En

za

9
D

-6

SO
M
D

C

.

t
os
am

M

SARS-CoV-2

Camostat
Nafamostat

80

0

ta

SO

t

D

C

am

os

ta

SO
M
D

G

C

D

C

**

0

0

En

M

SO

os
ta
t
am

M
D

am
C

*

**

am

20

*

.

40

*

*

100

za

60

*

80

120

En

80

100

9

Relative entry efficiency (%)

100

**

140

120

**

Calu-3

-6

**

120
Relative entry efficiency (%)

DHT

F

H460

D

CSS

E

SO

os
ta
t

SO
M
D

H460

*

0

AR

D

*

50

AR

TMPRSS2

Relative entry efficiency (%)

HIV backbone
Pseudovirus

60

*

1 00

D

Nano
Luciferase

80

*

AR

ACE2

n.s

SO

Nano
Luciferase

100

M

S protein

Relative entry efficiency (%)

Relative entry efficiency (%)

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342782; this version posted October 16, 2020. The copyright holder for this preprint
SARS-CoV-2
1 50 the preprint in perpetuity. It is made
120
(which was Pseudovirus
not certified by peer review) is the author/funder,
who has granted bioRxiv a license to display
available under aCC-BY-NC-ND 4.0 International license.
Infection assay

